Icatibant

Drug Profile

Icatibant

Alternative Names: Firazyr; HOE-140; Icatibant acetate; JE-049

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Jerini; sanofi-aventis; Shire
  • Class Kinins; Neuropeptides; Oligopeptides
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Capillary leak syndrome; Hereditary angioedema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Preregistration Submission Withdrawal Angioedema
  • No development reported Capillary leak syndrome; Liver cirrhosis
  • Discontinued Arrhythmias; Musculoskeletal pain; Myocardial infarction; Pancreatitis; Rhinitis

Most Recent Events

  • 10 Nov 2016 Efficacy, adverse events and pharmacokinetic data from a phase III trial in Hereditary angioedema (In adolescents, In children) presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2016)
  • 21 Mar 2016 Efficacy data from the phase II AMACE trial in Angioedema (ACE inhibitor-induced) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 16 Feb 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top